MedImmune’s Greenleaf, Clovis Oncology’s Mahaffy to Deliver Keynotes at 2012 Mid-Atlantic Bio Conference

MedImmune’s Greenleaf, Clovis Oncology’s Mahaffy to Deliver Keynotes at 2012 Mid-Atlantic Bio Conference

Wills & Associates Public RelationsBrad Wills, 240-752-7171or:Mid-Atlantic BioShelly Jobst, 703-442-2010

The today announced that two industry-leading executives will deliver keynote addresses at the nationally recognized conference taking place on September 27-28 at the Bethesda North Marriott Hotel & Conference in Bethesda, Md.

Patrick J. Mahaffy, president and CEO of Boulder, Colorado-based , a biopharmaceutical company, will deliver opening remarks Thursday, September 27. Peter Greenleaf, president of , the Gaithersburg, Maryland-based global biologics arm of , will speak at the Conference’s closing luncheon Friday, September 28.

“The Mid-Atlantic Bio Conference is a great venue to explore the many transformations taking place in our industry and I’m honored to give the opening remarks,” Mahaffy said. “I look forward to sharing my thoughts about company and product development in these interesting and complicated times.”

“Mid-Atlantic Bio plays a vital role in fostering continued growth of the biosciences community and making this region a hub for innovation,” Greenleaf said. “I am honored to have the opportunity to speak at the conference and share insights on the industry trends and forces impacting developing bioscience companies – including opportunities and risks associated with the ongoing U.S. health care reform debate.”

“It is a critical time for the biotech community everywhere, and we are pleased to have Peter and Patrick join us this year to provide their unique perspectives on our industry,” said Art Jacoby, CEO of the , and one of the conference co-hosts. “This conference is the ideal forum in which we all can convene to share ideas and work to impact the business, financial and policy climates that are imperative to continued innovation and business success.”

Patrick J. Mahaffy is a co-founder of Clovis Oncology and has served as the President and CEO and on the board of directors since the Company’s inception. Clovis Oncology focuses on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. Clovis Oncology targets its development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis has additional offices in San Francisco, California and Cambridge, UK.

Prior to founding Clovis, Mr. Mahaffy served as President and CEO and on the board of directors at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. Additionally, he is a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University.

As President of MedImmune, Greenleaf has led one of the largest biotechnology employers nationally and one of the founding companies of the Mid-Atlantic biocluster. During his tenure, Greenleaf has led the company’s rapid growth, adding nearly 700 employees per year and expanding the reach of each of MedImmune's campuses worldwide and opened an award-winning manufacturing facility in Frederick, Md. Under his leadership, MedImmune struck a biotech-industry-first manufacturing capacity sharing deal with a major pharmaceutical company.

Greenleaf previously led the development of MedImmune’s global marketing and portfolio organizations, as well as the broader commercial, corporate development and strategy functions. He chairs the , which implements the State’s venture capital initiative, and serves on the board of directors of the , the world's largest biotech trade organization. He holds a Bachelor of Science degree from Western Connecticut State University and a Master's degree in business administration from St. Joseph's University.

The Mid-Atlantic Bio conference will bring together nearly 1,000 industry stakeholders – including entrepreneurs, representatives from start-ups, small to midsize and developing companies, as well as larger established companies, capital sources, researchers and universities, public policymakers, suppliers and service providers – from approximately 30 states and 10 countries. Over the course of two days, attendees will engage in company presentations, policy discussions, educational workshops, partnering and business development meetings, investor presentations, media briefings and innovation exhibitions. The Mid-Atlantic Bio Conference is presented by the , , and the . For more information or to register please visit .

Mid-Atlantic Bio – taking place September 27-28 in Bethesda, Md. – is one of the country’s premier biotech conferences for senior-level executives, policymakers, academia, financiers, media and service providers. Its proximity to the US government, federal labs, commercial research and development, academic centers of excellence and a growing investment community, make it a uniquely valuable venue for those in the life sciences community. First launched in 2005, the conference is a joint initiative of the founding host organizations: the Mid-Atlantic Venture Association, the Virginia Biotechnology Association, and the Technology Council of Maryland. The Conference is also pleased to welcome the North Carolina Biotechnology Center as a strategic partner for 2012. For more information, please visit .